The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Correspondence
PreviousPrevious
Volume 337:1389 November 6, 1997 Number 19
NextNext

Heparin-Induced Thrombocytopenia with Thromboembolic Arterial Occlusion Treated with Recombinant Hirudin

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
-Purchase this article

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited

More Information
To the Editor: Lepirudin (Refludan) is a genetically engineered recombinant form of hirudin that is used for anticoagulation therapy in patients with heparin-induced thrombocytopenia due to heparin-dependent antiplatelet antibodies.1 We report a case of combined intraoperative and postoperative lepirudin treatment of a patient with heparin-induced thrombocytopenia and acute arterial occlusion.

A 60-year-old woman (weight, 71 kg; height, 160 cm) had been receiving 7500 IU of unfractionated heparin sodium twice a day subcutaneously for five days for prophylaxis against venous thrombosis while a paraspinal cystic lesion in the region of the thoracic spine was being investigated. She was transferred to our . . . [Full Text of this Article]

References



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.